Case report

Molecular diagnosis and ocular imaging of varicella zoster virus associated neuroretinitis

Rene Y. Choi\textsuperscript{a}, Andreas Lauer\textsuperscript{b}, James T. Rosenbaum\textsuperscript{a,b,c,}\textsuperscript{*}

\begin{flushleft}
\textsuperscript{a} Department of Ophthalmology, Casey Eye Institute, Oregon Health & Science University, Portland, OR, USA
\textsuperscript{b} Department of Medicine, Oregon Health & Science University, Portland, OR, USA
\textsuperscript{c} Legacy Devers Eye Institute, Legacy Health System, Portland, OR, USA
\end{flushleft}

A 30-year-old man was referred to our clinic for a 1-week history of decreased vision in his left eye and ulcerative skin lesions above his left eyebrow. On exam, he had clinical findings consistent with neuroretinitis characterized by optic disc edema and formation of a macular star. Polymerase chain reaction analysis of aqueous fluid was positive for varicella zoster virus. He was treated with oral valacyclovir with excellent resolution of his symptoms and clinical findings.

1. Introduction

Neuroretinitis is a rare disease entity characterized by unilateral vision loss, optic disc edema, and macular star formation from lipid exudates. It is thought to be governed by an infectious or immune-mediated process that may be precipitated by various agents. \textit{Bartonella henselae} and \textit{quintana} are organisms most commonly associated with neuroretinitis; however, others include toxoplasmosis, syphilis, Lyme, and tuberculosis.\textsuperscript{1–5} Neuroretinitis has also been associated with systemic diseases such as sarcoidosis, inflammatory bowel disease, and polyarteritis nodosa.\textsuperscript{6–8}

Varicella zoster virus associated neuroretinitis (VZVAN) has always been a presumptive diagnosis based on serology or presence of zoster-like cutaneous lesions.\textsuperscript{9–12} To the best of our knowledge, we report for the first time a case of VZVAN confirmed by polymerase chain analysis of ocular tissue.

2. Case report

A 30-year-old man presented with a 1-week history of decreased vision in his left eye and ulcerative skin lesions above his left eyebrow. On exam, he had clinical findings consistent with neuroretinitis characterized by optic disc edema and formation of a macular star. Polymerase chain reaction analysis of aqueous fluid was positive for varicella zoster virus. He was treated with oral valacyclovir with excellent resolution of his symptoms and clinical findings.

Conclusions and importance: Varicella zoster virus is a rare cause of neuroretinitis. We report for the first time a case of varicella zoster virus associated neuroretinitis confirmed by polymerase chain reaction analysis of ocular fluid. Molecular testing of ocular tissue may lead to a definitive diagnosis.
(HSV2), and VZV polymerase chain reaction (PCR) analysis, which yielded a positive result only for VZV.

At his 7-week follow up visit, his visual acuity was 20/20 in the left eye. He did note a small scotoma slightly to the left of his central vision. He had a quiescent AC along with resolution of disc edema and macular thickening (Fig. 2A). OCT (B) shows retinal thickening, intraretinal fluid, and exudates. Valacyclovir was reduced to a maintenance dose of 1 g a day. Eight months after his initial presentation, his exam remained stable.

3. Discussion

Neuroretinitis is an inflammatory disorder characterized by optic disc edema and formation of a macular star from lipid exudates. It has been closely linked to infectious agents such as Bartonella henselae and Toxocara canis. We are aware of only four reported cases of varicella zoster virus associated neuroretinitis (VZVAN) in adults. For each, a presumptive diagnosis was made with either serology or the presence of typical VZV skin lesions that appeared in temporal proximity to the neuroretinitis. We report a case of VZV neuroretinitis confirmed via PCR analysis of aqueous fluid.

Our case is of particular interest because our patient had Bartonella henselae IgG serology titers that were equivocal. However, he tested negative for IgM levels, which should be elevated in the acute phase. He also had the typical cutaneous vesicular lesions consistent with VZV. Most importantly, PCR testing of his aqueous fluid was negative for Bartonella henselae.

It was noted that both our patient’s brother and father had a history of shingles at around 30 years of age. Family history is a known risk factor for shingles. Furthermore, the risk increases with multiple blood relatives. Whether family history plays a role in VZVAN requires further investigation.

Given the rarity of VZVAN, there are no definite guidelines for management. Previous reports included the use of systemic anti-viral medications (acyclovir, valacyclovir), steroids, and observation. Favorable outcomes with visual acuities of 20/25 or better were reported in all cases. Our patient received valacyclovir at a dosing regimen similar to that used in acute retinal necrosis. His visual acuity improved from 20/50 to 20/20 in the affected eye; however, whether this resulted from therapy or was the natural course of the disease is difficult to ascertain.

4. Conclusions

To our knowledge, this is the first report of VZVAN confirmed with PCR testing. VZV may be a cause for neuroretinitis in immunocompetent individuals. Molecular biology testing of ocular tissue may be helpful in arriving at a definitive diagnosis.

Patient consent

The patient consented to publication of the case in writing.

Acknowledgements and disclosures

Funding

The authors receive support from an unrestricted grant from Research to Prevent Blindness, New York, NY and P30 EY010572 core grant from the National Institutes of Health, Bethesda, Maryland.

Conflicts of interest

James Rosenbaum receives support from the William and Mary Bauman Foundation, the Stan and Madelle Rosenfeld Family Trust, and the Spondylitis Association of America. The following authors have no financial disclosures: (AL, RC).

Authorship

All authors attest that they meet the current ICMJE criteria for Authorship.

Acknowledgements

None.

References

1. George JG, Bradley JC, Kimbrough 3rd RC, Shami MJ. Bartonella quintana associated neuroretinitis. Scand J Infect Dis. 2006;38:127–128.
2. Moreno RJ, Weisman J, Waller S. Neuroretinitis: an unusual presentation of ocular toxoplasmosis. Ann Ophthalmol. 1992;24:68–70.
3. Arruga J, Valentines J, Mauri F, Roca G, Salom R, Ruji G. Neuroretinitis in acquired syphilis. Ophthalmology. 1985;92:262–270.
4. Karma A, Sternberg T, Summannen P, Immensen I, Mykila H, Seppala I. Long-term follow-up of chronic Lyme neuroretinitis. Retina. 1996;16:505–509.
5. Steschschulte SU, Kim RF, Cunningham Jr ET. Tuberculous neuroretinitis. J Neuro Ophthalmol. 1999;19:201–204.
6. Kosmorsky GS, Prayson R. Primary optic pathway sarcoidosis in a 38-year-old white man. J Neuro Ophthalmol. 1996;16:188–190.
7. Shoari M, Katz RJ. Recurrent neuroretinitis in an adolescent with ulcerative colitis. J Neuro Ophthalmol. 2005;25:286–288.
8. Matsuda A, Chiu S, Ohashi T. A case of neuroretinitis associated with long-standing polyarteritis nodosa. Ophthalmologica. 1994;208:166–171.
9. Biswas J, Nagpal A, Chopra S, Karma S. Resolution of chicken pox neuroretinitis with oral acyclovir: a case report. Ocul Immunol Inflamm. 2003;11:315–318.
10. Finger RP, Sandhu SS, Harper CA. Atypical neuroretinitis in secondary chickenpox.
11. Tsao WS, He MS, Tsai RK. Varicella zoster virus-associated neuroretinitis. *Taiwan J Ophthalmol.* 2015;5:189–191.

12. Nicaeus T, Wilhelm H. [Bilateral neuroretinitis with zoster infection]. *Klin Monbl Augenheilkd.* 1999;214:175–177.

13. Purvin V, Sundaram S, Kawasaki A. Neuroretinitis: review of the literature and new observations. *J Neuro Ophthalmol.* 2011;31:58–68.

14. Hicks LD, Cook-Norris RH, Mendoza N, Madkan V, Arora A, Tyring SK. Family history as a risk factor for herpes zoster: a case-control study. *Arch Dermatol.* 2008;144:603–608.

15. Taylor SR, Hamilton R, Hooper CY, et al. Valacyclovir in the treatment of acute retinal necrosis. *BMC Ophthalmol.* 2012;12:48.